(Q26471439)

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole in autism spectrum disorders and fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole for the treatment of irritability associated with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole for maladaptive behavior in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

21 January 2018

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

7 January 2021

inferred from DOI database lookup

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Prevalence of autism-spectrum conditions: UK school-based population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

The effects of haloperidol on learning and behavior in autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Global prevalence of autism and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole: profile on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Risperidone for autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole versus other atypical antipsychotics for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Management of Children With Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Antipsychotics in the treatment of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

The PedsQL: measurement model for the pediatric quality of life inventory

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Systematic review of prevalence studies of autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

The Overt Aggression Scale for the objective rating of verbal and physical aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole for Autism Spectrum Disorders (ASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Aripiprazole for autism spectrum disorders (ASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009043.PUB3

Critical analysis of the disability in Parkinson's disease

21 January 2018

1 reference

12 December 2020

Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder.

1 reference

12 December 2020

Antipsychotics and the risk of type 2 diabetes mellitus in children and youth

1 reference

12 December 2020